University of California Davis School of Medicine, Sacramento, California.
Department of Surgery, University of California Davis, Sacramento, California.
J Surg Res. 2024 Mar;295:53-60. doi: 10.1016/j.jss.2023.09.064. Epub 2023 Nov 20.
Adrenal hemorrhage (AH) can occur due to multiple etiologies with variable radiographic appearance, often indistinguishable from underlying adrenal neoplasms. There is a lack of AH literature and evidence-based guidelines. Our study aimed to understand the prevalence and etiology of AH, follow-up, and incidence of underlying neoplasm.
An institutional database was queried from January 2006 to October 2021 for patients with AH on imaging, excluding patients with known malignancies, adrenal masses, or prior adrenal surgery. Demographics, medical history, hematoma size, laterality, biochemical evaluation, intervention, and additional imaging were reviewed.
Of 490,301 imaging reports queried, 530 (0.11%) with AH met inclusion criteria. Most imaging (n = 485, 91.5%) was performed during trauma evaluation. Two patients underwent dedicated intervention at presentation. Interval imaging was performed in 114 (21.5%) patients at a median of 2.6 (interquartile range 0.99-13.4) mo, with resolution (n = 84, 73.7%) or decreased size of AH (n = 21, 18.4%) in most patients. Only 10 patients (1.9%) saw an outpatient provider in our system to address AH or evaluate for underlying mass, and 9 (1.7%) underwent biochemical screening. Thirteen patients (11% of 118 patients with any follow-up) had evidence of an adrenal mass, confirmed on serial imaging (n = 10) or adrenalectomy (n = 3). Scans performed for nontrauma indications were significantly more likely to have an underlying mass (n = 6/26 [23.1%]) than those performed for trauma evaluation (n = 7/92 [7.6%], P = 0.04).
AH is a rare finding associated with an increased rate of underlying adrenal mass, particularly when unrelated to trauma. Most AH resolves spontaneously without intervention. Follow-up imaging at 6 mo can help distinguish mass-associated AH from simple hemorrhage.
由于多种病因,肾上腺出血(AH)可发生不同的影像学表现,常与潜在的肾上腺肿瘤难以区分。目前缺乏关于 AH 的文献和循证指南。我们的研究旨在了解 AH 的患病率、病因、随访和潜在肿瘤的发生率。
我们从 2006 年 1 月至 2021 年 10 月对影像学检查发现的肾上腺出血患者进行了一项机构数据库检索,排除已知恶性肿瘤、肾上腺肿块或既往肾上腺手术的患者。回顾了患者的人口统计学、病史、血肿大小、侧别、生化评估、干预措施和其他影像学检查。
在 490301 份影像学报告中,有 530 份(0.11%)符合纳入标准。大多数影像学检查(n=485,91.5%)是在创伤评估期间进行的。有 2 名患者在就诊时进行了专门的干预。114 名患者(21.5%)在中位数为 2.6(四分位距 0.99-13.4)月时进行了间隔影像学检查,大多数患者的 AH 消退(n=84,73.7%)或血肿缩小(n=21,18.4%)。仅有 10 名患者(1.9%)在我们的系统中接受了门诊医生的诊治,以处理 AH 或评估潜在肿块,9 名患者(1.7%)进行了生化筛查。13 名患者(118 名有任何随访患者中的 13 名)有肾上腺肿块的证据,通过连续影像学检查(n=10)或肾上腺切除术(n=3)证实。由于非创伤原因进行的检查比由于创伤进行的检查更有可能发现潜在的肿块(n=6/26 [23.1%]比 n=7/92 [7.6%],P=0.04)。
AH 是一种罕见的发现,与潜在肾上腺肿块的发生率增加有关,尤其是与创伤无关时。大多数 AH 可自发消退而无需干预。6 个月时的随访影像学检查有助于区分与肿块相关的 AH 和单纯性出血。